Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Long-Term Investments (2020 - 2025)

Universe Pharmaceuticals' Long-Term Investments history spans 6 years, with the latest figure at $702.3 million for Q3 2025.

  • For Q3 2025, Long-Term Investments rose 98475.71% year-over-year to $702.3 million; the TTM value through Sep 2025 reached $702.3 million, up 98475.71%, while the annual FY2025 figure was $702.3 million, 98475.71% up from the prior year.
  • Long-Term Investments for Q3 2025 was $702.3 million at Universe Pharmaceuticals, up from $712494.0 in the prior quarter.
  • Across five years, Long-Term Investments topped out at $702.3 million in Q3 2025 and bottomed at $685307.0 in Q3 2023.
  • The 5-year median for Long-Term Investments is $712494.0 (2024), against an average of $149.9 million.
  • The largest annual shift saw Long-Term Investments plummeted 98.44% in 2022 before it skyrocketed 98475.71% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $45.1 million in 2021, then tumbled by 98.44% to $702890.0 in 2022, then dropped by 2.5% to $685307.0 in 2023, then rose by 3.97% to $712494.0 in 2024, then surged by 98475.71% to $702.3 million in 2025.
  • Per Business Quant, the three most recent readings for UPC's Long-Term Investments are $702.3 million (Q3 2025), $712494.0 (Q3 2024), and $685307.0 (Q3 2023).